Bachelor?s degree in Biochemistry/Molecular Biology University of California, Santa Barbara (1989) and doctorate in Molecular Pathology University of California, San Diego (1997). Obtained the title of Livre Docente (2011) Department of Radiology, in the area of Basic Oncology, FMUSP. Currently is a Medical Research Coordinator and director of the Viral Vector Laboratory in the Center of Translational Investigation in Oncology (CTO), Cancer Institute of Sao Paulo (ICESP). Also is a member of the Nucleus for the Convergence of Life Sciences, Physics and Engineering for Innovation in Diagnostics and Therapies (NAP IDx&T) as well as a member of the International Committee of the American Society of Gene and Cell Therapy. Has experience in the area of Biochemistry and Molecular Biology, with emphasis in Gene Therapy, acting principally in the following topics: viral vectors; tumor suppressor genes; immune modulating genes; cancer; genetic modification of stem cells; cardiovascular and hematopoietic diseases; animal models. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Brazil is increasingly positioned to compete in the field of advanced therapies. In particular, five gene therapy products have been registered with ANVISA, paving the way for new proposals for clinical evaluation. Our group has invested in the development of an intervention for melanoma that uses improved adenoviral vectors to deliver two genes, p14ARF and interferon-beta, which cooperat…
The burden of cancer on patient care and public health systems continues to grow, in part due to the aging population. Effective treatment for cancer is often not available, though new and improved approaches are being developed. Gene therapy has been in clinical use for over 25 years and its use for the treatment of cancer has shown several successes, including recent approval by the FDA…
Melanoma is an especially difficult tumor to treat once it has metastasized. Traditional approaches, such as chemotherapy with dacarbazine, are limited in their efficacy while newer drugs, such as vemurafanib (B-Raf inhibitor), are associated with acquired resistance to therapy. However, since 90% of melanomas retain wild-type p53, we propose this genotype may provide advantages that favo…
(Only some records are available in English at this moment)
One of the goals for cancer treatment is the induction of oncolysis and antitumor immune response. For example, radiotherapy and chemotherapy drugs are known to induce immunogenic death. In the same way, gene therapy can also be used for this purpose, such as using oncolytic viruses, whether by the action of viral replication or the function of transgenes encoded by the vector. Previous w…
Prostate cancer is among the most common cancers in men worldwide. Despite treatment options, patients with metastatic disease have a five-year survival rate of only 29%, so development of new therapeutic strategies is needed in order to achieve long-term benefits. Treatment resistance mechanisms such as tumor heterogeneity and an immunosuppressive microenvironment prevent the establishme…
The immune system functions include regulation by immune checkpoints (ICPs) - pathways that either inhibit or activate the immune cells, mainly T lymphocytes. Cancer cells and Antigen Presenting Cells (APCs) found in the tumor microenvironment can express ICPs with different patterns, thus diminishing the immune response to the disease. Blocking the cytotoxic T-lymphocyte associated prote…
Melanoma is the most aggressive type of skin cancer and has a high lethality. A growing number of works have shown the relevance and benefits of gene therapy in treating cancer, including melanoma. In this context, recent research points to vaccination involving neoantigens as a promising strategy in the treatment of this malignancy. Previous results from the research group conducted by P…
Although metastatic melanoma is the least prevalent among skin cancers, it is the most lethal due to resistance to currently available treatments. Therefore, new effective therapeutic approaches are urgently needed. An interesting feature of melanoma is the presence of wild-type p53 protein, which in spite of being inactive represents an important therapeutic target since its modulation m…
(Only some records are available in English at this moment)
The advent of immunotherapy has revolutionized cancer treatment, especially for melanomas, which are tumors with high mutational load and are notably immunogenic. However, immune checkpoint inhibitor therapies are not efficient for a significant share of patients, yet combined strategies have reported additional antitumoral effects. In the research project developed in Brazil, we observed…
Colorectal cancer remains a challenge despite recent advances in treatment. It is the third most common carcinoma and the second cause of cancer related death. There is a plethora of genetic alterations linked to development and progression of colorectal cancer, though these varied phenotypes are unified by disruption in the balance between tumor suppressor and oncogenic pathways, often i…
Among the current strategies to use the immune system to treat cancer patients, the blockade of immune checkpoints has yielded highly encouraging results in several clinical trials. Recent work in Dr. Schreiber`s laboratory has used a combination of next generations sequencing, bioinformatics and state-of-the-art immunology techniques to shown that tumor specific T cells reactivated upon …
| 1 / 1 | Ongoing research grants |
| 10 / 5 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 28 / 18 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 2 / 2 | Completed scholarships abroad |
| 44 / 29 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID